RE:RE:Conference de CanaccordI also thought it was a good presentation Aldo. And like you I was a bit shocked when Galbraith said the company had to start over in terms of the quality assurance system and basically had to rerun the batches all over again to ensure FDA standards were met all at a cost of $100M. You have to wonder how previous management could get this so wrong. Everyone knows quality assurance is paramount especially given all the nasty things that can be transmitted with blood products. With priority review the company is supposed to have access to the FDA to help in BLA preparation so these issues should have been caught early especially since it involved a novel new process. And what about the process specialists in Rockville? It is hard to believe they got it so wrong first time around. In any event the BLA will be refiled in the next few weeks and Galbraith seems confident it will be accepted and granted a Pdufa date in Q1 next year. Let’s see if it happens!